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Background
The timing of surgery in asymptomatic patients with aor-
tic stenosis (AS) is controversial. Adverse LV remodeling
is related to prognosis in AS. Cardiovascular magnetic
resonance (CMR) can identify diffuse and focal myocar-
dial fibrosis, by T1 mapping and late gadolinium
enhancement (LGE) respectively, as well as myocardial
perfusion reserve (MPR), which is inversely related to
symptoms and an independent predictor of exercise
capacity in severe AS. The aim of this study was to deter-
mine whether MPR and other CMR markers of LV remo-
deling are of prognostic value in asymptomatic AS.
Methods
Asymptomatic patients with moderate to severe AS and
matched healthy controls were recruited in this prospec-
tive, multi-centre study, and underwent echocardiogra-
phy and a stress CMR at 3T. CMR analysis was blinded
and undertaken in a core lab. Investigations were not
reported unless there was a clinical indication. Patients
were followed for 12-30 months and outcomes were
adjudicated by 2 independent Cardiologists, blinded to
test results. Clinical outcome was a composite of: the
development of typical symptoms, major adverse
cardiovascular events or aortic valve replacement over a
median follow-up of 18 months.
Results
174 patients and 23 controls were recruited. Compared
to controls, LV volumes, mass, MPR and LGE were sig-
nificantly different in patients, but there was no signifi-
cant difference in ECV. 60 patients had a clinical event
during follow-up (34.5%). There was no difference in
comorbidities between those with and without an out-
come. After adjusting for sex: AS severity, MPR, val-
vulo-arterial impedance and LV mass/volume were
univariate predictors of the outcome. CMR measures of
fibrosis (LGE, native T1 and ECV) did not predict out-
come. On stepwise multivariate analysis, severe AS (HR
0.17 (0.07-0.43) p = 0.0002) and MPR (HR 0.60 (0.40-
0.92) p = 0.0197) were independent predictors of
outcome.
Conclusions
MPR, but not markers of fibrosis, is a predictor of out-
come in initially asymptomatic patients with AS. Further
randomized trials are needed to determine whether
MPR can improve outcomes in asymptomatic AS.
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Table 1 Demographic, echocardiographic and CMR data for patients and controls
AS Patients (n = 174) Healthy Controls (n = 23) p-value
Age (years) 66.2 ± 13.3 68.3 ± 8.8 0.331
Male (n (%)) 133 (76.4) 16 (69.6) 0.471
Echocardiography data
AV Vmax (m/s) 3.86 ± 0.56 1.35 ± 0.27 <0.001*
AVAI (cm2/m2) 0.57 ± 0.14 1.71 ± 0.36 <0.001*
Lateral E/e’ 9.88 ± 3.72 8.07 ± 2.97 0.026*
VAI (Echo) (mmHg/ml/m2) 3.96 ± 1.06 3.67 ± 0.76 0.220
CMR data
LVEDVI (ml/m2) 87.58 ± 18.27 78.16 ± 9.40 <0.001*
LVESVI (ml/m2) 38.28 ± 10.65 32.11 ± 5.03 <0.001*
LVEF (%) 56.7 ± 4.95 58.9 ± 3.67 0.044*
LVMI (g/m2) 57.69 ± 13.85 44.31 ± 7.20 <0.001*
LV mass/volume (g/ml) 0.66 ± 0.11 0.57 ± 0.08 <0.001*
VAI (MRI) (mmHg/ml/m2) 3.81 ± 0.82 3.50 ± 0.74 0.078
Global MPR 2.27 ± 0.70 3.16 ± 0.65 <0.001*
LGE present (n,%) 82 (47.1) 5 (21.7) 0.025*
% LGE (%) 4.20 ± 3.76 2.00 ± 2.21 <0.001*
Native myocardial T1 (ms) 1131.9 ± 69.54 1092.3 ± 34.29 <0.001*
ECV (%) 24.82 ± 2.43 25.05 ± 2.57 0.680
AV Vmax=peak aortic jet velocity, AVAI=aortic valve area indexed to BSA, VAI=valvulo-arterial impedance, LVEDVI=left ventricular end-diastolic volume indexed to
BSA, LVESVI=left ventricular end systolic volume indexed to BSA, LVEF=left ventricular ejection fraction, LVMI=left ventricular mass indexed to BSA,
MPR=myocardial perfusion reserve, LGE=late gadolinium enhancement, ECV=extracellular volume fraction
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